Experience in the Design and Production of Recombinant Oral Vaccine «Revax VZT»

Objective of the work was the production of recombinant vaccine «RevaxVZT» in tablet dosage form against hepatitis B and pathogenic for humans orthopoxviruses for further clinical trials. Materials and methods. Recombinant strain b7.5S2-S of vaccinia virus carrying a DNA fragment of hepatitis B virus inserted into thymidinekinase gene was used as an active component of the vaccine. Microbiological, virological, physical, physical and chemical, and biotechnological methods were used for studying the quality of the drug and technological processes. Results and discussion. Results of technological control for semi-finished products and final products of the vaccine “Revax VZT” showed the possibility of using certified hardware-processing line of “TEOVac” for its manufacturing. Same technology can be potentially used with other live tableted embryo smallpox vaccines too. For the development of the vaccine “Revax VZT” with the specific activity of not less than 1.0·107 PFu/tablet, it is necessary to use a dry virus-containing material with activity not less than 2.0·108 PFU/g which is produced by freeze-drying of liquid virus-containing preparation with the activity of not less than 1.0·108 PFU/g, preferentially propagated from chorionic allantoic membranes of chicken embryos as a substrate for viral biomass accumulation

Assessment of Animal Sensitivity to Particularly Dangerous Orthopoxviruses, Using Primary Cultures of Lung Cells

Objective of the study is to investigate the sensitivity of different animals to highly pathogenic Orthopoxviruses applying techniques, based on utilization of primary cultures of lung cells, and to assess the possibility of further deployment of this approach. Materials and methods. Cultural and virological research methods are used. Results and conclusions. Performed is the assessment of sensitivity of outbred mice, marmots and chickens to variola virus (VV) and monkeypox virus (MPV), using suspended primary cultures of lung cells (SPCLC) of these animals. Through inoculation of the mentioned above cell cultures with VV and MPV in a dose of 0.00001 PFU per a cell (plaque forming unit /cell) demonstrated has been virus replication with maximum concentration values in all cases (1,4 - 2,0 lg PFU/ml), mainly 3 days after infection. According to the data on SPCLC, sensitivity to VV in mice, marmots and chickens (ID50 - 50 % infective dose) amounts to (1,3 ± 0,5) lg PFU; (2,3 ± 0,5) lg PFU; and (0,0 ± 0,4) lg PFU respectively, taking into account unhindered interaction of the virus with permissive lung cells in the organism of the animals. As for MPV values for this indicator, they are: (1,7 ± 0,3) lg PFU for mice, and (0,5 ± 0,3) lg PFU - for marmots. Obtained ID50 values for VV using mice SPCLC and for MPV using mice and marmots SPCLC coincide with the ones, studied in direct experiments on intranasal infection with the viruses, with regard to 10 % of the viral application in lungs when deploying the latter method of infection. The fact testifies to the possibility of further deployment of this method for the assessment of animal sensitivity to highly pathogenic Orthopoxviruses based on the results of in vitro experiments

УСПЕШНОЕ ЛЕЧЕНИЕ ОБШИРНОГО ГЛУБОКОГО ОЖОГА У РЕБЕНКА С ЕДИНСТВЕННОЙ ЛЕВОЙ ПОЧКОЙ И ОТСУТСТВИЕМ СЕЛЕЗЕНКИ

We report a case of successful treatment in a child with extensive deep burns of the trunk and lower limbs with a flame in the absence of the right kidney and spleen.Представлен случай успешного лечения ребенка с обширным глубоким ожогом пламенем туловища и нижних конечностей при отсутствии у пациента правой почки и селезенки

Approaches to Reduce Adverse Effect of Vaccinia Virus in Orally Immunized Mice

Objective of the investigation was to model the adverse action of vaccinia virus (VV), caused by oral immunization of mice and to evaluate efficacy of its reduction, using therapeutic and prophylactic drugs. Materials and methods. Virological and immunological research methods were used. Results and conclusions. Reproduced was pathological action of VV in the orally infected mice. The ability to reduce the side effect and protect mice from lethal infection was demonstrated by such preparations as Metisazon, Likopid, and NIOCH-14 orally administered in the investigated schemes. Moreover preliminary single oral immunization with TEOVak smallpox vaccine before oral infection with Neurovaccine-92 strain of VV also lowered pathogenic effect and protected mice against death. All the investigated schemes of drug administration did not affect the immune response if used alongside with TEOVak smallpox vaccine and can be deployed to develop safe schemes of primary oral vaccination against smallpox. In addition, such drugs as Ribomunil, Immudon, Ingavirin can be used as means to enhance the immune response to smallpox vaccines

SUCCESSFUL TREATMENT OF THE TRUNK AND LOWER LIMBS EXTENSIVE DEEP BURN IN A CHILD WITH ONE KIDNEY (LEFT) IN THE ABSENCE OF SPLEEN

We report a case of successful treatment in a child with extensive deep burns of the trunk and lower limbs with a flame in the absence of the right kidney and spleen

Evolution of cortical neurons supporting human cognition

Human cognitive abilities are generally thought to arise from cortical expansion over the course of human brain evolution. In addition to increased neuron numbers, this cortical expansion might be driven by adaptations in the properties of single neurons and their local circuits. We review recent findings on the distinct structural, functional, and transcriptomic features of human cortical neurons and their organization in cortical microstructure. We focus on the supragranular cortical layers, which showed the most prominent expansion during human brain evolution, and the properties of their principal cells: pyramidal neurons. We argue that the evolutionary adaptations in neuronal features that accompany the expansion of the human cortex partially underlie interindividual variability in human cognitive abilities